Difference between revisions of "Nortriptyline-bupropion"

From Psychiatrienet
Jump to: navigation, search
 
Line 3: Line 3:
 
| to = bupropion  
 
| to = bupropion  
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of nortriptyline to a maximum of 50 mg/day, when this dosage is > 50 mg/day.
+
{{stopNortriptyline}}
* '''Day 1-3:''' reduce dosage of nortriptyline to 25 mg/day.
 
 
| start =  
 
| start =  
 
* '''Day 1:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of nortriptyline according to the scheme above.
 
* '''Day 1:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of nortriptyline according to the scheme above.

Latest revision as of 16:25, 28 October 2015

Nortriptyline
Type Antidepressant
Group TCA
links
Medscape Nortriptyline
PubChem 4543
PubMed Nortriptyline
Kompas (Dutch) Nortriptyline
Wikipedia Nortriptyline
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion

Switch medication from nortriptyline to bupropion.[1] [2]

Nietinrijdenbord.png Stop nortriptyline
  • Before day 1: gradually reduce dosage of nortriptyline to a maximum of 50 mg/ day, when this dosage is > 50 mg/day.
  • Day 1-3: reduce dosage of nortriptyline to 25 mg/day.
  • Day 4-7: reduce dosage of nortriptyline to 10 mg/day.
  • Day 8: stop administration of nortriptyline.
Eenrichtingbord.png Start bupropion
  • Day 1: simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of nortriptyline according to the scheme above.
  • Day 8: stop administration of nortriptyline and continue administration of bupropion.
Infobord.png More information
  • Bupropion is a strong inhibitor of CYP2D6, which metabolizes nortriptyline.
  • Caution with this switch is necessary.
  • The concomitant use of bupropion and tricyclic antidepressants (TCAs) may potentiate the risk of seizures. These agents are all epileptogenic and may have additive effects on the seizure threshold.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.